Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )
Clinical trial NCT01569295 · COMPLETED
Trial details
- NCT number
- NCT01569295
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2012-06-15
- Primary completion
- 2019-06-10
- Enrollment
- 416
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.